Compare NICE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | INDV |
|---|---|---|
| Founded | 1986 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | 1999 | 2014 |
| Metric | NICE | INDV |
|---|---|---|
| Price | $104.68 | $34.85 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $153.46 | N/A |
| AVG Volume (30 Days) | 345.7K | ★ 1.5M |
| Earning Date | 05-14-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | ★ $11.21 | $21.37 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $83.10 | $22.30 |
| 52 Week High | $153.07 | $42.81 |
| Indicator | NICE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 42.27 |
| Support Level | $96.03 | $32.06 |
| Resistance Level | $104.84 | $35.54 |
| Average True Range (ATR) | 3.52 | 0.86 |
| MACD | -0.08 | 0.17 |
| Stochastic Oscillator | 52.22 | 55.79 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).